The information platform of the non-clinical safety evaluation research institution of drugs was put into operation
Time of Update: 2022-12-30
From the date of issuance of the circular, GLP institutions, relevant provincial drug administrations, and food and drug review and inspection centers of the State Medical Products Administration (hereinafter referred to as verification centers) shall log in to the GLP institution information platform and promptly fill in GLP institution information, GLP certification status, supervision and inspection results of GLP institutions, investigation and punishment of illegal acts, and other information.
ACE-LY-003 Phase II trial results update: aclotinib has shown good efficacy and safety in relapsed/refractory marginal zone lymphoma
Time of Update: 2022-11-04
Poke "Read Original" to see moreAs of January 4, 2022, a total of 43 patients with R/R MZL received aclotinib monotherapy (100 mg BID until disease progression or intolerable toxicity).
p53 drugs in cancer: one protein, multiple targets
Time of Update: 2022-10-20
In 2002, chemical drug screening found that PRIMA-1 (p53 reactivation induces mass apoptosis1), a compound that restores wtp53 function after binding to mutp53, triggers apoptosis in vitro in transducing Saos-2 cells expressing the R273H mutant protein (p53 (R273H)) and inhibits tumor formation in vivo through these cells 。 Like PRIMA-1, MIRA-1 and STIMA-1 also have Michael receptor activity and can potentially modify cysteine in the p53 protein to stabilize wild-type conformations and prevent mutp53 from unfolding.
After 4 years! "Symptomatic intracranial atherosclerotic stenosis intravascular treatment of Chinese expert consensus 2022" released
Time of Update: 2022-10-14
Restenosis and prevention The risk of asymptomatic restenosis recurrent stroke is relatively low, and follow-up under drug therapy is recommended in principle; Patients with symptomatic severe restenosis who do not respond to pharmacotherapy may be considered for treatment by vascular intervention (C-EO level evidence, moderately recommended).
Rational diet action, everyone participates in the initial formation
Time of Update: 2022-09-03
The new national standard can better meet the nutritional needs of infants and young children, especially the adjustment of the nutrient content range, and put forward higher requirements for the raw material control, formula design and process management of production enterprises .
Recently, a large number of pharmacies have been fined
Time of Update: 2022-05-09
For example, recently, the State Food and Drug Administration announced five typical cases of special drug safety rectification, and a chain pharmacy was fined 1.
It is understood that the Drug Supervision Department of the State Food and Drug Administration has recently held a special inspection work conference on drug distribution and use .
Tianjing Biotech announces that the Phase 2 clinical trial of TJ107 and PD-1 antibody combination drug has been approved by NMPA to start
Time of Update: 2021-11-16
The company announced today that the Center for Drug Evaluation of the National Medical Products Administration of China has formally approved the initiation of the combination of efilinterleukin alpha (also known as TJ107/GX-I7/NT-I7) and PD-1 antibody in the treatment of advanced solid tumors (including three negative Breast cancer and head and neck cancer) phase 2 clinical trials .
221 pharmacies do not allow bonuses
Time of Update: 2021-11-03
In the interpretation of the "Notice", the Hebei Provincial Medical Insurance Bureau pointed out that the inclusion of designated retail pharmacies in the "dual-channel" management must meet the following three conditions: one is to realize the circulation and traceability of electronic prescriptions; the other is to upload drugs in real time.
Nasopharyngeal cancer immunotherapy! Junshi bio-anti-PD-1 therapy Terripri monoanti (toyo®) and chemotherapy first-line treatment application was accepted by NMPA
Time of Update: 2021-02-26
29 February 2021 / -- TopAlliance Biosciences recently announced that the National Drug Administration (NMPA) has accepted its own A new adaptive application for the developed anti-PD-1 monoantigen drug Terripri monoantigen (Toripalimab®): combined chemotherapy for relapsed metastatic nasopharyngeal cancer (NPC) in advanced first-line unsyscticed treatment.
Quickly and sensitively identify multidrive bacteria
Time of Update: 2020-12-11
In addition, RNA molecules can be used to detect resistant genes in bacterial genetic material.
The system allows them to detect RNA from a single antibiotic-resistant bacteria without having to enlarge or label the sample for analysis.
Botulinum toxin treats neck dystia! DaxibotulinumtoxinA Phase 3 clinical success, Fosun Pharma introduced to China development
Time of Update: 2020-10-22
Revance expects the results of another parallel Phase 3 open-label, long-term safety clinical trial, ASPEN-OLS, to be available in 2021, with 354 subjects in the group.
() Origin: Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia.
Green leaf pharmaceutical co-innovation drug Lurbinectedin is about to enter the clinic in China
Time of Update: 2020-10-21
Lurbinectedin's ORR reached 35%, and DoR's median 5.3-month Lurbinectedin was approved in the United States based on open label, multi-center, single-arm clinical data from SCLC adult patients (including platinum-sensitive and drug-resistant patients) who developed the disease after chemotherapy with a Lurbinectedin single drug.
Takeda HyQiva has been approved by the European Union to update the label: for adults, adolescents, children
Time of Update: 2020-10-13
Source: European Medicines Agencyapproves Label Update for HYQVIA® (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase), Expanding its Use to a Broader Group of Patients. Secondary Im
100 medical representatives were interviewed
Time of Update: 2020-10-06
industry for rebates, red envelopes and other governance has been carried out, and this for the treatment of pharmaceutical representatives has also increased efforts, recently a cancer hospital in Guangzhou issued a "medical representatives visit reception approval provisions" details.
The division of the pharmaceutical industry has intensified, and the leader of the innovative pharmaceutical industry chain is expected to benefit
Time of Update: 2020-09-11
A securities research report pointed out that it is optimistic about the dynamic adjustment of health insurance dividends, the supply of innovative drugs to improve, pay tilt, overlay review reform under the local innovative drugs IND (clinical trial declaration of new drugs) continued to reach a new high, is expected to usher in 2023-2026 domestic innovative drugs golden development period.